Novel clinical risk calculator for improving cancer predictability of mpMRI fusion biopsy in prostates
International Urology and Nephrology · 2024
DOI: 10.1007/s11255-024-04037-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Urology and Nephrology, 2024. Verfasst von Anthony Bruccoliere und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Department of Urology, Texas Tech University Health Sciences Center, 3601-4 Street STOP 7260, Lubbock, TX, 79430-7260, USA. Hauptthemen laut MEDLINE: Multiparametric Magnetic Resonance Imaging, Prostatic Neoplasms, Image-Guided Biopsy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 17 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: Prostate Imaging-Reporting and Data System (PI-RADS) assists in evaluating lesions on multiparametric magnetic resonance imaging (mpMRI), but there are still ongoing efforts in improving the predictive value for the presence of clinically significant PCa (csPCa) with a Gleason grade group ≥ 2 on Fusion-Biopsy. This pilot study intends to propose an easily implementable method for augmenting predictability of csPCa for PI-RADS. METHODS: A cohort of 151 consecutive patients underwent mpMRI Fusion and random US Biopsy as a result of having at least one PI-RADS lesion grade 3-5 between January 1, 2019 and December 31, 2022. A single radiologist reads all films in this study applying PI-RADS V2. RESULTS: Of the 151 consecutive patients, 49 had a highest lesion of PI-RADS 3, 82 had a highest lesion of PI-RADS 4, and 20 had a highest lesion of PI-RADS 5. For each respective group, 12, 42, and 18 patients had proven csPCa. Two predictive models for csPCa were created by employing a logistical regression with parameters readily available to providers. The models had an AUC of 0.8133 and 0.8206, indicating promising effective models. CONCLUSION: PI-RADS classification has relevant predictability problems for grades 3 and 4. By applying the presented risk calculators, patients with PI-RADS 3 and 4 are better stratified, and thus, a significant number of patients can be spared biopsies with potential complications, such as infection and bleeding. The presented predictive models may be a valuable diagnostic tool, adding additional information in the clinical decision-making process for biopsies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Medicine, Department of Urology, Texas Tech University Health Sciences Center, 3601-4 Street STOP 7260, Lubbock, TX, 79430-7260, USA.
- Department of Radiology, University Medical Center, Lubbock, TX, 79415, USA.
- School of Medicine, Texas Tech University Health Sciences Center, Clinical Research Institute, Lubbock, TX, 79415, USA.
- School of Medicine, Department of Urology, Texas Tech University Health Sciences Center, 3601-4 Street STOP 7260, Lubbock, TX, 79430-7260, USA. Werner.Deriese@ttuhsc.edu.
Zitieren
APA
Bruccoliere, A., Tran, V., Helo, N., Awal, A., Stroever, S., & de Riese, W. T. W. (2024). Novel clinical risk calculator for improving cancer predictability of mpMRI fusion biopsy in prostates. International Urology and Nephrology. https://doi.org/10.1007/s11255-024-04037-1
Vancouver
Bruccoliere A, Tran V, Helo N, Awal A, Stroever S, de Riese WTW. Novel clinical risk calculator for improving cancer predictability of mpMRI fusion biopsy in prostates. International Urology and Nephrology. 2024. doi:10.1007/s11255-024-04037-1
BibTeX
@article{Bruccoliere2024,
author = {Bruccoliere, Anthony and Tran, Vivie and Helo, Naseem and Awal, Abdul and Stroever, Stephanie and de Riese, Werner T W},
title = {Novel clinical risk calculator for improving cancer predictability of mpMRI fusion biopsy in prostates},
journal = {International Urology and Nephrology},
year = {2024},
doi = {10.1007/s11255-024-04037-1}
}
EUVIMED